Johnson & Johnson Drug Pipeline

Johnson & Johnson maintains a substantial portfolio of clinical programs, with 847 trials registered since 2008, and 159 currently active. These active trials span from Phase 1 through Phase 4, with a distribution of 50, 48, 76, and 3 trials respectively. The portfolio covers 14 therapeutic areas, but is heavily concentrated in oncology, which accounts for approximately 70% of active programs (111 trials). Within oncology, the leading indications are solid tumor (advanced) with 33 active trials (10 in Phase 3), multiple myeloma with 29 active trials (13 in Phase 3), non-small cell lung cancer (NSCLC) with 13 active trials (4 in Phase 3), non-Hodgkin lymphoma with 10 active trials (1 in Phase 3), and hematologic malignancies with 9 active trials (2 in Phase 3). Outside of oncology, the next most active therapeutic areas are immunology (20 active trials), central nervous system (CNS) (3 active trials), infectious disease (3 active trials), cardiovascular (2 active trials), and rare disease (2 active trials). The significant number of Phase 3 trials in oncology suggests a potential for near-term clinical catalysts in this area.